EDITOR'S CHOICE IN ONCOLOGY
C. Ambrogio et al., “KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS,” Cell, 172:857-68.e15, 2018.
Genes in the RAS family regulate cell growth and differentiation, and mutations can render them oncogenic. One such proto-oncogene, KRAS, frequently turns up in human cancers, including lung cancer, and is associated with resistance to chemotherapies including MEK inhibitors.
Some proteins encoded by RAS genes appear to function as dimers—linked pairs of identical molecules. Pasi Jänne, a medical oncologist at Dana-Farber Cancer Institute, used a fluorescence resonance energy transfer (FRET) assay to find that the KRAS protein does, too. They then fashioned a mutant KRAS that was dimerization-deficient.
PARTNERS IN CRIME
Jänne and colleagues compared tumor development in mice with one copy of oncogenic KRAS and one copy of either wild-type KRAS or one that couldn’t dimerize. The mice with dimerization-deficient KRAS fared much better, suggesting that oncogenic KRAS must dimerize with wild-type KRAS to function pathogenically.
GETTING IN THE MIDDLE
“Most of the efforts so far on KRAS-mutant cancers have focused on trying to directly target KRAS itself, which has been a challenge, or to target immediate KRAS effector pathways,” says Jänne. Therapeutically targeting KRAS dimerization instead would be mutation-independent and pathway-specific, he says.
Marie Evangelista, an oncology researcher at Genentech, notes that the strategy comes with its own hurdles. “It’s unclear whether there are going to be any small molecules that can target that interface” between KRAS monomers, she says. “We’re going to need to have a better understanding of how that interface is formed to find out if there are any opportunities to really go after it.”